AbbVie, Regenxbio collaborate on potential gene therapy for wet AMD, DR
AbbVie has teamed up with biotechnology firm Regenxbio to develop and commercialise the latter’s investigational gene therapy RGX-314. RGX-314 is intended for the treatment of wet age-related macular